Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506922 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT00506922: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00506922 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00506922, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one antigen mismatched related donor transplantation. Secondary Objectives: 1. To determine safety of escalating doses of pentostatin in combination with tacrolimus and methotrexate. 2. To reduce the incidence of acute GVHD following transplants with unrelated donor to 40%. 3. To document blood levels of tacrolimus when combined with pentostatin.
Interventions
- DRUG Tacrolimus
- DRUG Methotrexate
- DRUG Pentostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2000-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506922
The ClinicalTrials.gov registry entry for NCT00506922 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT00506922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506922 about?
NCT00506922 is a clinical study titled "Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT". Primary Objective: 1\. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one antigen mismatched related donor transplantation. Secondary Objecti...
What is the current status of trial NCT00506922?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2000-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00506922?
The interventions under investigation include: Tacrolimus (DRUG), Methotrexate (DRUG), Pentostatin (DRUG).
Who is sponsoring clinical trial NCT00506922?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.